NVS Stock Analysis: Novartis | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 303.124m USD | 12M Return: 24.7% | US66987V1098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 353M
EPS Trend: 84.8%
Qual. Beats: 2
Rev. Trend: 93.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Novartis AG is a Swiss-headquartered pharmaceutical company that researches, develops, manufactures, and markets medicines globally. Its portfolio spans cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology, and hematology, with major products including Entresto for heart failure, Cosentyx for inflammatory conditions, Kisqali for breast cancer, Pluvicto for prostate cancer, Zolgensma for spinal muscular atrophy, and Leqvio for LDL cholesterol reduction. The company also maintains a license and collaboration agreement with Alnylam Pharmaceuticals to commercialize Leqvio (inclisiran).
As one of the worlds largest pharmaceutical manufacturers by market capitalization, Novartis operates a global drug development and commercialization business model that relies on patent-protected branded therapies sold across multiple geographies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland, with its ADR listed on the NYSE under the ticker NVS.
- Entresto patent cliff pressures near-term US revenue
- Pluvicto and Kisqali accelerate oncology segment growth
- Cost reduction program targets margin expansion through 2026
| Net Income: 10.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -3.23 > 1.0 |
| NWC/Revenue: -6.71% < 20% (prev -6.74%; Δ 0.03% < -1%) |
| CFO/TA 0.15 > 3% & CFO 17.3b > Net Income 10.0b |
| Net Debt (41.3b) to EBITDA (21.8b): 1.90 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.91b) vs 12m ago -1.80% < -2% |
| Gross Margin: 74.62% > 18% (prev 76.21%; Δ -1.59% > 0.5%) |
| Asset Turnover: 50.17% > 50% (prev 52.54%; Δ -2.37% > 0%) |
| Interest Coverage Ratio: 9.02 > 6 (EBIT TTM 14.2b / Interest Expense TTM 1.58b) |
| A: -0.03 (Total Current Assets 28.7b - Total Current Liabilities 32.5b) / Total Assets 117b |
| B: 0.33 (Retained Earnings 39.2b / Total Assets 117b) |
| C: 0.13 (EBIT TTM 14.2b / Avg Total Assets 112b) |
| D: 0.47 (Book Value of Equity 37.2b / Total Liabilities 79.6b) |
| Altman-Z'' = 2.22 = BBB |
| DSRI: 1.11 (Receivables 9.96b/8.98b, Revenue 56.3b/56.4b) |
| GMI: 1.02 (GM 76.21% / 74.62%) |
| AQI: 1.04 (AQ_t 0.65 / AQ_t-1 0.63) |
| SGI: 1.00 (Revenue 56.3b / 56.4b) |
| TATA: -0.06 (NI 10.0b - CFO 17.3b) / TA 117b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of November 22, 2026, the stock is trading at USD 150.47 with a total of 2,237,182 shares traded. Over the past week, the price has changed by -6.25%, over one month by -2.06%, over three months by -3.69% and over the past year by +24.68%.
Current recommended Stop Loss: 146.20 (which is 2.8% or 1.3 ATR below the current price).
Novartis has received a consensus analysts rating of 3.36. Therefore, it is recommended to hold NVS.
- StrongBuy: 2
- Buy: 3
- Hold: 4
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 157.1 | 4.4% |
P/E Trailing = 30.6298
P/E Forward = 16.0256
P/S = 5.2842
P/B = 8.1424
P/EG = 3.8176
Revenue TTM = 56.3b USD
EBIT TTM = 14.2b USD
EBITDA TTM = 21.8b USD
Long Term Debt = 36.7b USD (from longTermDebt, last quarter)
Short Term Debt = 9.93b USD (from shortTermDebt, last quarter)
Debt = 50.3b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.96b
Net Debt = 41.3b USD (calculated: Debt 50.3b - CCE 8.97b)
Enterprise Value = 344b USD (303b + Debt 50.3b - CCE 8.97b)
Interest Coverage Ratio = 9.02 (Ebit TTM 14.2b / Interest Expense TTM 1.58b)
EV/FCF = 23.21x (Enterprise Value 344b / FCF TTM 14.8b)
FCF Yield = 4.31% (FCF TTM 14.8b / Enterprise Value 344b)
FCF Margin = 26.36% (FCF TTM 14.8b / Revenue TTM 56.3b)
Net Margin = 17.82% (Net Income TTM 10.0b / Revenue TTM 56.3b)
Gross Margin = 74.62% ((Revenue TTM 56.3b - Cost of Revenue TTM 14.3b) / Revenue TTM)
Gross Margin QoQ = 75.99% (prev 74.47%)
Tobins Q-Ratio = 2.94 (Enterprise Value 344b / Total Assets 117b)
Interest Expense / Debt = 3.14% (Interest Expense 1.58b / Debt 50.3b)
Taxrate = 20.80% (2.63b / 12.6b)
NOPAT = 11.3b (EBIT 14.2b * (1 - 20.80%))
Current Ratio = 0.88 (Total Current Assets 28.7b / Total Current Liabilities 32.5b)
Debt / Equity = 1.35 (Debt 50.3b / totalStockholderEquity, last quarter 37.2b)
Debt / EBITDA = 1.90 (Net Debt 41.3b / EBITDA 21.8b)
Debt / FCF = 2.78 (Net Debt 41.3b / FCF TTM 14.8b)
Total Stockholder Equity = 40.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.94% (Net Income 10.0b / Total Assets 117b)
RoE = 24.56% (Net Income TTM 10.0b / Total Stockholder Equity 40.9b)
RoCE = 18.34% (EBIT 14.2b / Capital Employed (Equity 40.9b + L.T.Debt 36.7b))
RoIC = 12.28% (NOPAT 11.3b / Invested Capital 91.7b)
WACC = 5.28% (E(303b)/V(353b) * Re(5.74%) + D(50.3b)/V(353b) * Rd(3.14%) * (1-Tc(0.21)))
Discount Rate = 5.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.81 | Cagr: -3.12%
[DCF] Terminal Value 73.45% ; FCFF base≈15.7b ; Y1≈14.1b ; Y5≈11.8b
[DCF] Fair Price = 78.00 (EV 189b - Net Debt 41.3b = Equity 147b / Shares 1.89b; r=8.35% [WACC [floored]]; 5y FCF grow -13.01% → 2.50% )
EPS Correlation: 84.84 | EPS CAGR: 10.06% | SUE: 2.12 | # QB: 2
Revenue Correlation: 93.86 | Revenue CAGR: 7.68% | SUE: 0.78 | # QB: 0
EPS current Quarter (2027-03-31): EPS=2.27 | Chg30d=-2.58% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=9.07 | Chg30d=+2.69% | Revisions=+57% | GrowthEPS=+1.0% | GrowthRev=+1.9%
EPS next Year (2027-12-31): EPS=9.93 | Chg30d=+1.33% | Revisions=+44% | GrowthEPS=+9.5% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: +62% (up=9, down=1)